Aurinia Pharmaceuticals Inc.(AUPH)Earnings, Financials & Key Ratios

AUPH•NASDAQ

$16.04

$2.12B mkt cap·7.7× P/E·Price updated May 6, 2026

SectorHealthcare IndustryBiotechnology Sub-IndustryImmunology and Inflammation Therapies

AboutAurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.Show more

Revenue$283M+20.4%
EBITDA$105M+610.9%
Net Income$287M+4893.1%
EPS (Diluted)2.07+5167.2%
Gross Margin88.46%+0.5%
EBITDA Margin37.06%+490.5%
Operating Margin37.06%+1959.5%
Net Margin101.47%+4047.7%
ROE59.91%+3834.1%
ROIC16.58%+1986.5%
Debt/Equity0.13-38.8%

Technical→

AUPH Key Insights

Aurinia Pharmaceuticals Inc. (AUPH) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

✓Strong Piotroski F-Score: 7/9
✓FCF machine: 47.8% free cash flow margin
✓Strong 5Y sales CAGR of 41.4%
✓Share count reduced 5.1% through buybacks
✓Trading near 52-week high

✗Weaknesses

✗Low quality earnings: Net income not backed by cash flow

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

AUPH Price & Volume

Aurinia Pharmaceuticals Inc. (AUPH) stock price & volume — 10-year historical chart

Loading chart...

AUPH Growth Metrics

Aurinia Pharmaceuticals Inc. (AUPH) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years103.27%

5 Years41.38%

3 Years28.3%

TTM20.38%

Profit CAGR

10 Years-

5 Years-

3 Years-

TTM4893.08%

EPS CAGR

10 Years-

5 Years-

3 Years-

TTM4615.26%

Return on Capital

10 Years-26.72%

5 Years-13.06%

3 Years-0.87%

Last Year18.89%

AUPH Recent Earnings

Aurinia Pharmaceuticals Inc. (AUPH) EPS & revenue vs analyst estimates — last 4 quarters

Full history →

●Beat EPS 11/12 qtrs (92%)●Beat Revenue 8/12 qtrs (73%)

Q1 2026Latest

Feb 26, 2026

EPS

$0.26

Est $0.21

+23.8%

Revenue

$77M

Est $75M

+3.2%

Q4 2025

Nov 4, 2025

EPS

$0.23

Est $0.16

+43.8%

Revenue

$73M

Est $75M

-1.6%

Q3 2025

Jul 31, 2025

EPS

$0.16

Est $0.17

-5.9%

Revenue

$70M

Est $68M

+3.4%

Q2 2025

May 12, 2025

EPS

$0.16

Est $0.08

+100.0%

Revenue

$62M

Est $65M

-3.4%

Quarter	Date	EPS (Act vs Est)	Revenue (Act vs Est)
Q1 2026Latest	Feb 26, 2026	$0.26vs $0.21+23.8%	$77Mvs $75M+3.2%
Q4 2025	Nov 4, 2025	$0.23vs $0.16+43.8%	$73Mvs $75M-1.6%
Q3 2025	Jul 31, 2025	$0.16vs $0.17-5.9%	$70Mvs $68M+3.4%
Q2 2025	May 12, 2025	$0.16vs $0.08+100.0%	$62Mvs $65M-3.4%

Based on last 12 quarters of dataView full earnings history →

Company	Market Cap	Stock Price	P/E Ratio (TTM)	Revenue Growth 1Y	Net Margin	Return on Equity (ROE)	FCF Yield	Debt / Equity
LGNDLigand Pharmaceuticals IncorporatedDirect Competitor	4.57B	232.30	-1055.91	27.28%	19.34%	5.11%	1.7%	0.01
ANIPANI Pharmaceuticals, Inc.Direct Competitor	1.8B	84.63	25.49	43.78%	8.87%	14.49%	10.31%	0.60
PRAXPraxis Precision Medicines, Inc.Direct Competitor	7.5B	333.30	-24.73	-100%		-58.74%		0.00
CORTCorcept Therapeutics IncorporatedDirect Competitor	5.51B	51.34	62.61	12.79%	6.23%	7.5%	2.57%	0.01
GSKGSK plcProduct Competitor	101.32B	50.38	6.67	4.11%	19.19%	31.48%	7.81%	1.11
BIIBBiogen Inc.Product Competitor	27.92B	189.13	21.42	1.39%	13.92%	7.55%	7.34%	0.38
ALNYAlnylam Pharmaceuticals, Inc.Product Competitor	40.18B	301.11	129.23	65.19%	13.46%	98.29%	1.16%	1.62
VKTXViking Therapeutics, Inc.Product Competitor	3.63B	31.31	-9.82			-71.31%		0.00

Compare AUPH vs Peers

Aurinia Pharmaceuticals Inc. (AUPH) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs LGND

Most directly comparable listed peer for AUPH.

Scale Benchmark

vs GSK

Larger-name benchmark to compare AUPH against a more recognizable public peer.

Peer Set

Compare Top 5

vs LGND, ANIP, PRAX, CORT

AUPH Income Statement

Aurinia Pharmaceuticals Inc. (AUPH) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25
Sales/Revenue	420K	463K	318K	50.12M	45.6M	134.03M	175.51M	235.13M	283.06M
Revenue Growth %	142.77%	10.24%	-31.32%	15660.38%	-9%	193.89%	30.95%	33.97%	20.38%
Cost of Goods Sold	1K	41.38M	0	0	1.09M	5.66M	14.15M	28.25M	32.66M
COGS % of Revenue	0.24%	8937.8%	-	-	2.39%	4.23%	8.06%	12.01%	11.54%
Gross Profit	419K▲ 0%	-40.92M▼ 9865.9%	318K▲ 100.8%	50.12M▲ 15660.4%	44.51M▼ 11.2%	128.37M▲ 188.4%	161.37M▲ 25.7%	206.88M▲ 28.2%	250.39M▲ 21.0%
Gross Margin %	99.76%	-8837.8%	100%	100%	97.61%	95.77%	91.94%	87.99%	88.46%
Gross Profit Growth %	147.93%	-9865.87%	100.78%	15660.38%	-11.18%	188.37%	25.71%	28.21%	21.03%
Operating Expenses	47.48M	56.62M	91.26M	154.41M	225.25M	239.84M	253.06M	211.57M	145.48M
OpEx % of Revenue	11305.24%	12229.16%	28698.43%	308.09%	493.91%	178.94%	144.18%	89.98%	51.4%
Selling, General & Admin	12.1M	13.67M	22.34M	97.27M	171.44M	196.37M	195.04M	172.03M	101.79M
SG&A % of Revenue	2880%	2953.35%	7024.53%	194.09%	375.92%	146.51%	111.12%	73.16%	35.96%
Research & Development	33.93M	41.38M	52.87M	50.33M	51.14M	44.99M	49.64M	20.79M	32.51M
R&D % of Revenue	8078.57%	8937.8%	16624.53%	100.42%	112.13%	33.57%	28.28%	8.84%	11.48%
Other Operating Expenses	195K	2.06M	16.06M	6.81M	2.67M	-1.52M	8.38M	18.76M	11.18M
Operating Income	-47.06M▲ 0%	-56.16M▼ 19.3%	-90.94M▼ 61.9%	-104.29M▼ 14.7%	-180.74M▼ 73.3%	-111.47M▲ 38.3%	-91.69M▲ 17.7%	-4.69M▲ 94.9%	104.91M▲ 2338.4%
Operating Margin %	-11205.48%	-12129.16%	-28598.43%	-208.09%	-396.31%	-83.17%	-52.24%	-1.99%	37.06%
Operating Income Growth %	-106.29%	-19.33%	-61.94%	-14.68%	-73.3%	38.32%	17.74%	94.89%	2338.4%
EBITDA	-45.61M	-54.59M	-89.77M	-102.92M	-177.97M	-108.76M	-80.04M	14.76M	104.91M
EBITDA Margin %	-10858.81%	-11791.14%	-28230.19%	-205.35%	-390.25%	-81.15%	-45.61%	6.28%	37.06%
EBITDA Growth %	-113.77%	-19.7%	-64.44%	-14.64%	-72.93%	38.89%	26.41%	118.44%	610.9%
D&A (Non-Cash Add-back)	1.46M	1.56M	1.17M	1.37M	2.76M	2.71M	11.65M	19.45M	0
EBIT	-47.06M	-55.91M	-90.94M	-104.29M	-180.21M	-106.35M	-74.69M	12.28M	0
Net Interest Income	1.04M	2.23M	2.7M	1.52M	529K	5.12M	14.22M	12.13M	0
Interest Income	1.04M	2.23M	2.7M	1.52M	529K	5.12M	17M	16.97M	13.57M
Interest Expense	0	0	0	0	0	0	2.77M	4.83M	-4.33M
Other Income/Expense	-23.73M	2.23M	2.7M	1.52M	529K	5.12M	14.22M	12.13M	9.24M
Pretax Income	-70.79M▲ 0%	-64.05M▲ 9.5%	-88.24M▼ 37.8%	-102.77M▼ 16.5%	-180.21M▼ 75.3%	-106.35M▲ 41.0%	-77.47M▲ 27.2%	7.45M▲ 109.6%	114.16M▲ 1432.7%
Pretax Margin %	-16855.24%	-13833.05%	-27748.74%	-205.06%	-395.15%	-79.35%	-44.14%	3.17%	40.33%
Income Tax	0	73K	144K	-94K	760K	1.83M	551K	1.7M	-173.04M
Effective Tax Rate %	0%	-0.11%	-0.16%	0.09%	-0.42%	-1.72%	-0.71%	22.77%	-151.59%
Net Income	-70.79M▲ 0%	-64.12M▲ 9.4%	-88.39M▼ 37.8%	-102.68M▼ 16.2%	-180.97M▼ 76.2%	-108.18M▲ 40.2%	-78.02M▲ 27.9%	5.75M▲ 107.4%	287.2M▲ 4893.1%
Net Margin %	-16855.24%	-13848.81%	-27794.03%	-204.88%	-396.81%	-80.71%	-44.45%	2.45%	101.47%
Net Income Growth %	-203.89%	9.42%	-37.84%	-16.17%	-76.24%	40.22%	27.88%	107.37%	4893.08%
Net Income (Continuing)	-70.79M	-64.12M	-88.39M	-102.68M	-180.97M	-108.18M	-78.02M	5.75M	287.2M
Discontinued Operations	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0
EPS (Diluted)	-0.92▲ 0%	-0.76▲ 17.4%	-1.33▼ 75.0%	-0.87▲ 34.6%	-1.40▼ 60.9%	-0.76▲ 45.7%	-0.54▲ 28.9%	0.04▲ 107.3%	2.07▲ 5167.2%
EPS Growth %	-39.39%	17.39%	-75%	34.59%	-60.92%	45.71%	28.95%	107.28%	5167.18%
EPS (Basic)	-0.92	-0.76	-1.33	-0.87	-1.40	-0.76	-0.54	0.04	2.14
Diluted Shares Outstanding	76.95M	84.78M	93.02M	118.47M	129.37M	141.91M	143.24M	146.19M	138.7M
Basic Shares Outstanding	76.92M	84.78M	93.02M	118.47M	129.37M	141.91M	143.24M	143.06M	134.37M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-

AUPH Balance Sheet

Aurinia Pharmaceuticals Inc. (AUPH) balance sheet — assets, liabilities & shareholders' equity

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25
Total Current Assets	175.25M	132.85M	315.14M	419.43M	513.32M	442.54M	424.8M	446.6M	491.97M
Cash & Short-Term Investments	173.46M	125.86M	306.02M	398.33M	466.08M	389.39M	350.49M	358.48M	398M
Cash Only	165.63M	117.97M	306.02M	272.35M	231.9M	94.17M	48.88M	83.43M	80.21M
Short-Term Investments	7.83M	7.89M	0	125.98M	234.18M	295.22M	301.61M	275.04M	317.78M
Accounts Receivable	109K	217K	368K	0	15.41M	13.48M	24.09M	36.54M	41.45M
Days Sales Outstanding	94.73	171.07	422.39	-	123.37	36.72	50.1	56.73	53.45
Inventory	-109K	0	0	13.93M	19.33M	24.75M	39.7M	39.23M	45.69M
Days Inventory Outstanding	-	-	-	-	6.47K	1.6K	1.02K	506.88	510.54
Other Current Assets	0	0	0	1.02M	796K	1.33M	1.03M	1.13M	6.83M
Total Non-Current Assets	14.6M	13.02M	9.16M	44.23M	30.04M	28.32M	123.26M	104.05M	259.62M
Property, Plant & Equipment	31K	41K	93K	10.28M	9.8M	8.56M	116.57M	98.87M	79.57M
Fixed Asset Turnover	13.55x	11.29x	3.42x	4.88x	4.65x	15.66x	1.51x	2.38x	3.56x
Goodwill	0	0	0	0	0	0	0	0	0
Intangible Assets	14.12M	12.62M	8.86M	9.33M	8.4M	6.42M	4.98M	4.36M	3.76M
Long-Term Investments	0	0	0	24.38M	0	0	201K	0	0
Other Non-Current Assets	448K	358K	209K	247K	11.84M	13.34M	1.52M	823K	93K
Total Assets	189.85M▲ 0%	145.86M▼ 23.2%	324.3M▲ 122.3%	463.66M▲ 43.0%	543.37M▲ 17.2%	470.86M▼ 13.3%	548.06M▲ 16.4%	550.64M▲ 0.5%	751.59M▲ 36.5%
Asset Turnover	0.00x	0.00x	0.00x	0.11x	0.08x	0.28x	0.32x	0.43x	0.38x
Asset Growth %	233.08%	-23.17%	122.33%	42.97%	17.19%	-13.34%	16.4%	0.47%	36.49%
Total Current Liabilities	8.15M	7.26M	11.29M	32M	40.65M	46.11M	77.19M	97.76M	93.72M
Accounts Payable	3.77M	2.95M	4.15M	2.63M	3.88M	3.09M	4.33M	5.19M	3.31M
Days Payables Outstanding	1000K	26.03	-	-	1.3K	198.93	111.63	67.02	37.02
Short-Term Debt	0	0	0	0	0	0	0	0	17.59M
Deferred Revenue (Current)	118K	118K	118K	0	190K	3.15M	4.81M	11M	3.72M
Other Current Liabilities	2.22M	1.92M	0	6.41M	4.45M	2.03M	1.59M	66.5M	72.41M
Current Ratio	21.50x	18.30x	27.90x	13.11x	12.63x	9.60x	5.50x	4.57x	5.25x
Quick Ratio	21.52x	18.30x	27.90x	12.67x	12.15x	9.06x	4.99x	4.17x	4.76x
Cash Conversion Cycle	-	-	-	-	5.29K	1.43K	962.8	496.58	526.98
Total Non-Current Liabilities	15.95M	26.03M	14.41M	23.91M	23.63M	19.32M	92.92M	75.4M	76.53M
Long-Term Debt	0	0	0	0	0	0	0	0	57.22M
Capital Lease Obligations	0	0	0	7.62M	7.68M	7.15M	82.01M	64.3M	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	15.51M	25.7M	14.2M	16.3M	15.95M	12.17M	10.91M	11.11M	19.31M
Total Liabilities	24.1M	33.29M	25.7M	55.91M	64.28M	65.42M	170.11M	173.17M	170.26M
Total Debt	0	0	0	8.41M	8.74M	8.09M	97.61M	79.37M	74.81M
Net Debt	-165.63M	-117.97M	-306.02M	-263.94M	-223.16M	-86.08M	48.73M	-4.06M	-5.4M
Debt / Equity	-	-	-	0.02x	0.02x	0.02x	0.26x	0.21x	0.13x
Debt / EBITDA	-	-	-	-	-	-	-	5.38x	0.71x
Net Debt / EBITDA	-	-	-	-	-	-	-	-0.28x	-0.05x
Interest Coverage	-	-	-	-	-	-	-33.04x	-0.97x	-
Total Equity	165.74M▲ 0%	112.58M▼ 32.1%	298.6M▲ 165.2%	407.75M▲ 36.6%	479.09M▲ 17.5%	405.44M▼ 15.4%	377.95M▼ 6.8%	377.48M▼ 0.1%	581.33M▲ 54.0%
Equity Growth %	361.04%	-32.08%	165.25%	36.55%	17.5%	-15.37%	-6.78%	-0.13%	54%
Book Value per Share	2.15	1.33	3.21	3.44	3.70	2.86	2.64	2.58	4.19
Total Shareholders' Equity	165.74M	112.58M	298.6M	407.75M	479.09M	405.44M	377.95M	377.48M	581.33M
Common Stock	499.2M	504.65M	746.49M	944.33M	1.18B	1.19B	1.2B	1.19B	1.12B
Retained Earnings	-351.84M	-415.96M	-472.48M	-575.16M	-756.12M	-864.3M	-942.32M	-936.57M	-649.37M
Treasury Stock	0	0	0	0	0	0	0	0	0
Accumulated OCI	-883K	-805K	-805K	-805K	-852K	-1.06M	-730K	-647K	-599K
Minority Interest	0	0	0	0	0	0	0	0	0

AUPH Cash Flow Statement

Aurinia Pharmaceuticals Inc. (AUPH) cash flow — operating, investing & free cash flow history

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25
Cash from Operations	-41.17M	-51.61M	-63.59M	-69.86M	-157.69M	-79.53M	-33.46M	44.39M	135.66M
Operating CF Margin %	-9802.14%	-11146.87%	-19995.28%	-139.39%	-345.78%	-59.34%	-19.06%	18.88%	47.93%
Operating CF Growth %	-120%	-25.36%	-23.2%	-9.87%	-125.73%	49.57%	57.93%	232.66%	205.62%
Net Income	-70.79M	-64.12M	-88.39M	-102.68M	-180.97M	-108.18M	-78.02M	5.75M	287.2M
Depreciation & Amortization	1.46M	1.56M	1.17M	1.37M	2.76M	2.71M	11.65M	19.45M	9.27M
Stock-Based Compensation	4.24M	6.86M	7.41M	17.45M	31.24M	32.3M	45.31M	31.6M	14.68M
Deferred Taxes	23.99M	9.97M	0	0	0	0	0	0	-176.19M
Other Non-Cash Items	-1.77M	118K	14.19M	9.48M	10.9M	462K	-6.79M	-17.85M	702K
Working Capital Changes	1.7M	-6M	2.03M	4.52M	-21.63M	-6.82M	-5.61M	5.45M	0
Change in Receivables	-23K	-108K	-151K	-13.62M	-15.41M	1.93M	-10.61M	-12.46M	-4.91M
Change in Inventory	0	0	0	-13.93M	-5.64M	-9.07M	-15.87M	477K	-6.46M
Change in Payables	2.17M	-888K	0	13.62M	4.08M	-792K	1.24M	860K	-1.87M
Cash from Investing	-8M	-66K	7.78M	-158.19M	-103.87M	-60.63M	-6.71M	39.26M	-32.77M
Capital Expenditures	-25K	-75K	-85K	-7.34M	-1.5M	-292K	-718K	-281K	-252K
CapEx % of Revenue	5.95%	16.2%	26.73%	14.65%	3.29%	0.22%	0.41%	0.12%	0.09%
Acquisitions	0	45K	0	1.76M	-1.2M	0	0	0	0
Investments	-	-	-	-	-	-	-	-	-
Other Investing	-7.98M	-45K	-16K	-1.76M	-16.63M	-663K	-11.86M	-43K	0
Cash from Financing	175.15M	4.01M	243.85M	194.38M	221.11M	2.43M	-5.13M	-49.09M	-106.11M
Debt Issued (Net)	0	0	-127K	0	0	0	-10.03M	-11.99M	0
Equity Issued (Net)	1000K	0	1000K	1000K	1000K	0	0	-1000K	0
Dividends Paid	0	0	0	0	0	0	0	0	0
Share Repurchases	0	0	0	0	0	0	0	-40.24M	-98.16M
Other Financing	12.83M	4.01M	20.86M	6.64M	24.37M	2.43M	4.89M	3.14M	-106.11M
Net Change in Cash	125.98M▲ 0%	-47.66M▼ 137.8%	188.05M▲ 494.6%	-33.67M▼ 117.9%	-40.45M▼ 20.1%	-137.73M▼ 240.5%	-45.3M▲ 67.1%	34.56M▲ 176.3%	-3.22M▼ 109.3%
Free Cash Flow	-41.19M▲ 0%	-51.69M▼ 25.5%	-63.69M▼ 23.2%	-77.2M▼ 21.2%	-159.19M▼ 106.2%	-79.82M▲ 49.9%	-34.18M▲ 57.2%	44.11M▲ 229.0%	135.41M▲ 207.0%
FCF Margin %	-9808.1%	-11163.07%	-20027.04%	-154.04%	-349.07%	-59.55%	-19.47%	18.76%	47.84%
FCF Growth %	-119.84%	-25.47%	-23.22%	-21.22%	-106.21%	49.86%	57.18%	229.05%	206.99%
FCF per Share	-0.54	-0.61	-0.68	-0.65	-1.23	-0.56	-0.24	0.30	0.98
FCF Conversion (FCF/Net Income)	0.58x	0.80x	0.72x	0.68x	0.87x	0.74x	0.43x	7.72x	0.47x
Interest Paid	0	0	59K	0	257K	1.98M	0	0	0
Taxes Paid	0	0	0	0	257K	1.98M	496K	2.18M	0

AUPH Key Ratios

Aurinia Pharmaceuticals Inc. (AUPH) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-83.33%	-70.2%	-46.08%	-42.99%	-29.07%	-40.81%	-24.46%	-19.92%	1.52%	59.91%
Return on Invested Capital (ROIC)	-325.67%	-	-	-	-114.7%	-67.82%	-29.06%	-18.44%	-0.88%	16.58%
Gross Margin	97.69%	99.76%	-8837.8%	100%	100%	97.61%	95.77%	91.94%	87.99%	88.46%
Net Margin	-13465.32%	-16855.24%	-13848.81%	-27794.03%	-204.88%	-396.81%	-80.71%	-44.45%	2.45%	101.47%
Debt / Equity	-	-	-	-	0.02x	0.02x	0.02x	0.26x	0.21x	0.13x
Interest Coverage	-	-	-	-	-	-	-	-33.04x	-0.97x	-
FCF Conversion	0.80x	0.58x	0.80x	0.72x	0.68x	0.87x	0.74x	0.43x	7.72x	0.47x
Revenue Growth	-26.38%	142.77%	10.24%	-31.32%	15660.38%	-9%	193.89%	30.95%	33.97%	20.38%

AUPH SEC Filings & Documents

Aurinia Pharmaceuticals Inc. (AUPH) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

Material company update

Apr 3, 2026·SEC

Material company update

Mar 23, 2026·SEC

Material company update

Feb 26, 2026·SEC

10-K Annual Reports

FY 2026

Feb 26, 2026·SEC

FY 2025

Feb 27, 2025·SEC

FY 2024

Feb 15, 2024·SEC

10-Q Quarterly Reports

FY 2025

Nov 4, 2025·SEC

FY 2025

Jul 31, 2025·SEC

FY 2025

May 12, 2025·SEC

AUPH Frequently Asked Questions

Aurinia Pharmaceuticals Inc. (AUPH) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Aurinia Pharmaceuticals Inc. (AUPH) reported $283.1M in revenue for fiscal year 2025. This represents a 36131% increase from $0.8M in 1998.

Aurinia Pharmaceuticals Inc. (AUPH) grew revenue by 20.4% over the past year. This is strong growth.

Yes, Aurinia Pharmaceuticals Inc. (AUPH) is profitable, generating $287.2M in net income for fiscal year 2025 (101.5% net margin).

Dividend & Returns

Aurinia Pharmaceuticals Inc. (AUPH) has a return on equity (ROE) of 59.9%. This is excellent, indicating efficient use of shareholder capital.

Aurinia Pharmaceuticals Inc. (AUPH) generated $135.4M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

Explore More AUPH

Aurinia Pharmaceuticals Inc. (AUPH) financial analysis — history, returns, DCA and operating performance tools

Total Return Calculator

Historical returns with dividends reinvested

→

DCA Calculator

Dollar cost averaging vs lump sum

→

Dividend History

Yield, growth, payout safety & DRIP

→

Earnings History

EPS trends, net income & profitability

→

Price History

Long-term charts & historical price data

→

Revenue History

Sales growth patterns & revenue breakdown

→

Financial Ratios

30 years of market, efficiency and balance-sheet ratios

→

Valuation

DCF intrinsic value, peer multiples & estimates

→

Aurinia Pharmaceuticals Inc.(AUPH)Earnings, Financials & Key Ratios

AUPH Key Insights

✓Strengths

✗Weaknesses

AUPH Price & Volume

AUPH Growth Metrics

Revenue CAGR

Profit CAGR

EPS CAGR

Return on Capital

AUPH Recent Earnings

AUPH Peer Comparison

Compare AUPH vs Peers

vs LGND

vs GSK

Compare Top 5

AUPH Income Statement

AUPH Balance Sheet

AUPH Cash Flow Statement

AUPH Key Ratios

AUPH SEC Filings & Documents

8-K Announcements

10-K Annual Reports

10-Q Quarterly Reports

AUPH Frequently Asked Questions

Explore More AUPH

Total Return Calculator

DCA Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios

Valuation